United States Biologic Drugs Market Report 2017

October 2017 | 99 pages | ID: U25E0455C6BPEN
QYResearch

Abstracts

In this report, the United States Biologic Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:

• The West
• Southwest
• The Middle Atlantic
• New England
• The South
• The Midwest
• with sales (volume), revenue (value), market share and growth rate of Biologic Drugs in these regions, from 2012 to 2022 (forecast).

United States Biologic Drugs market competition by top manufacturers/players, with Biologic Drugs sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including

• Roche
• Abbott Laboratories
• Johnson & Johnson
• Merck & Co.
• Pfizer
• Amgen
• Sanofi
• Novartis
• Eli Lilly
• Amgen

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

• Humira
• Remicade
• Rituxan
• Enbrel
• Lantus
• Avastin
• Herceptin
• Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Biologic Drugs for each application, including

• Diabetes
• Inflammation
• Auto-Immune Diseases
• Blood Diseases
• Cardiovascular Diseases
• Others

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

United States Biologic Drugs Market Report 2017

1 BIOLOGIC DRUGS OVERVIEW

1.1 Product Overview and Scope of Biologic Drugs
1.2 Classification of Biologic Drugs by Product Category
  1.2.1 United States Biologic Drugs Market Size (Sales Volume) Comparison by Type (2012-2022)
  1.2.2 United States Biologic Drugs Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
  1.2.3 Humira
  1.2.4 Remicade
  1.2.5 Rituxan
  1.2.6 Enbrel
  1.2.7 Lantus
  1.2.8 Avastin
  1.2.9 Herceptin
  1.2.10 Others
1.3 United States Biologic Drugs Market by Application/End Users
  1.3.1 United States Biologic Drugs Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
  1.3.2 Diabetes
  1.3.3 Inflammation
  1.3.4 Auto-Immune Diseases
  1.3.5 Blood Diseases
  1.3.6 Cardiovascular Diseases
  1.3.7 Others
1.4 United States Biologic Drugs Market by Region
  1.4.1 United States Biologic Drugs Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 The West Biologic Drugs Status and Prospect (2012-2022)
  1.4.3 Southwest Biologic Drugs Status and Prospect (2012-2022)
  1.4.4 The Middle Atlantic Biologic Drugs Status and Prospect (2012-2022)
  1.4.5 New England Biologic Drugs Status and Prospect (2012-2022)
  1.4.6 The South Biologic Drugs Status and Prospect (2012-2022)
  1.4.7 The Midwest Biologic Drugs Status and Prospect (2012-2022)
1.5 United States Market Size (Value and Volume) of Biologic Drugs (2012-2022)
  1.5.1 United States Biologic Drugs Sales and Growth Rate (2012-2022)
  1.5.2 United States Biologic Drugs Revenue and Growth Rate (2012-2022)

2 UNITED STATES BIOLOGIC DRUGS MARKET COMPETITION BY PLAYERS/SUPPLIERS

2.1 United States Biologic Drugs Sales and Market Share of Key Players/Suppliers (2012-2017)
2.2 United States Biologic Drugs Revenue and Share by Players/Suppliers (2012-2017)
2.3 United States Biologic Drugs Average Price by Players/Suppliers (2012-2017)
2.4 United States Biologic Drugs Market Competitive Situation and Trends
  2.4.1 United States Biologic Drugs Market Concentration Rate
  2.4.2 United States Biologic Drugs Market Share of Top 3 and Top 5 Players/Suppliers
  2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Biologic Drugs Manufacturing Base Distribution, Sales Area, Product Type

3 UNITED STATES BIOLOGIC DRUGS SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2012-2017)

3.1 United States Biologic Drugs Sales and Market Share by Region (2012-2017)
3.2 United States Biologic Drugs Revenue and Market Share by Region (2012-2017)
3.3 United States Biologic Drugs Price by Region (2012-2017)

4 UNITED STATES BIOLOGIC DRUGS SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2012-2017)

4.1 United States Biologic Drugs Sales and Market Share by Type (Product Category) (2012-2017)
4.2 United States Biologic Drugs Revenue and Market Share by Type (2012-2017)
4.3 United States Biologic Drugs Price by Type (2012-2017)
4.4 United States Biologic Drugs Sales Growth Rate by Type (2012-2017)

5 UNITED STATES BIOLOGIC DRUGS SALES (VOLUME) BY APPLICATION (2012-2017)

5.1 United States Biologic Drugs Sales and Market Share by Application (2012-2017)
5.2 United States Biologic Drugs Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities

6 UNITED STATES BIOLOGIC DRUGS PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 Roche
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Biologic Drugs Product Category, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Roche Biologic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 Abbott Laboratories
  6.2.2 Biologic Drugs Product Category, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Abbott Laboratories Biologic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Johnson & Johnson
  6.3.2 Biologic Drugs Product Category, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Johnson & Johnson Biologic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 Merck & Co.
  6.4.2 Biologic Drugs Product Category, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Merck & Co. Biologic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 Pfizer
  6.5.2 Biologic Drugs Product Category, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Pfizer Biologic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 Amgen
  6.6.2 Biologic Drugs Product Category, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Amgen Biologic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview
6.7 Sanofi
  6.7.2 Biologic Drugs Product Category, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 Sanofi Biologic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Main Business/Business Overview
6.8 Novartis
  6.8.2 Biologic Drugs Product Category, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 Novartis Biologic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.8.4 Main Business/Business Overview
6.9 Eli Lilly
  6.9.2 Biologic Drugs Product Category, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 Eli Lilly Biologic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.9.4 Main Business/Business Overview
6.10 Amgen
  6.10.2 Biologic Drugs Product Category, Application and Specification
    6.10.2.1 Product A
    6.10.2.2 Product B
  6.10.3 Amgen Biologic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.10.4 Main Business/Business Overview

7 BIOLOGIC DRUGS MANUFACTURING COST ANALYSIS

7.1 Biologic Drugs Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Biologic Drugs

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Biologic Drugs Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Biologic Drugs Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 UNITED STATES BIOLOGIC DRUGS MARKET SIZE (VALUE AND VOLUME) FORECAST (2017-2022)

11.1 United States Biologic Drugs Sales Volume, Revenue Forecast (2017-2022)
11.2 United States Biologic Drugs Sales Volume Forecast by Type (2017-2022)
11.3 United States Biologic Drugs Sales Volume Forecast by Application (2017-2022)
11.4 United States Biologic Drugs Sales Volume Forecast by Region (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer


The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Biologic Drugs
Figure United States Biologic Drugs Market Size (K Units) by Type (2012-2022)
Figure United States Biologic Drugs Sales Volume Market Share by Type (Product Category) in 2016
Figure Humira Product Picture
Figure Remicade Product Picture
Figure Rituxan Product Picture
Figure Enbrel Product Picture
Figure Lantus Product Picture
Figure Avastin Product Picture
Figure Herceptin Product Picture
Figure Others Product Picture
Figure United States Biologic Drugs Market Size (K Units) by Application (2012-2022)
Figure United States Sales Market Share of Biologic Drugs by Application in 2016
Figure Diabetes Examples
Table Key Downstream Customer in Diabetes
Figure Inflammation Examples
Table Key Downstream Customer in Inflammation
Figure Auto-Immune Diseases Examples
Table Key Downstream Customer in Auto-Immune Diseases
Figure Blood Diseases Examples
Table Key Downstream Customer in Blood Diseases
Figure Cardiovascular Diseases Examples
Table Key Downstream Customer in Cardiovascular Diseases
Figure Others Examples
Table Key Downstream Customer in Others
Figure United States Biologic Drugs Market Size (Million USD) by Region (2012-2022)
Figure The West Biologic Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Southwest Biologic Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Middle Atlantic Biologic Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure New England Biologic Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The South of US Biologic Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Midwest Biologic Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Biologic Drugs Sales (K Units) and Growth Rate (2012-2022)
Figure United States Biologic Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Biologic Drugs Market Major Players Product Sales Volume (K Units) (2012-2017)
Table United States Biologic Drugs Sales (K Units) of Key Players/Suppliers (2012-2017)
Table United States Biologic Drugs Sales Share by Players/Suppliers (2012-2017)
Figure 2016 United States Biologic Drugs Sales Share by Players/Suppliers
Figure 2017 United States Biologic Drugs Sales Share by Players/Suppliers
Figure United States Biologic Drugs Market Major Players Product Revenue (Million USD) (2012-2017)
Table United States Biologic Drugs Revenue (Million USD) by Players/Suppliers (2012-2017)
Table United States Biologic Drugs Revenue Share by Players/Suppliers (2012-2017)
Figure 2016 United States Biologic Drugs Revenue Share by Players/Suppliers
Figure 2017 United States Biologic Drugs Revenue Share by Players/Suppliers
Table United States Market Biologic Drugs Average Price (USD/Unit) of Key Players/Suppliers (2012-2017)
Figure United States Market Biologic Drugs Average Price (USD/Unit) of Key Players/Suppliers in 2016
Figure United States Biologic Drugs Market Share of Top 3 Players/Suppliers
Figure United States Biologic Drugs Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Biologic Drugs Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Biologic Drugs Product Category
Table United States Biologic Drugs Sales (K Units) by Region (2012-2017)
Table United States Biologic Drugs Sales Share by Region (2012-2017)
Figure United States Biologic Drugs Sales Share by Region (2012-2017)
Figure United States Biologic Drugs Sales Market Share by Region in 2016
Table United States Biologic Drugs Revenue (Million USD) and Market Share by Region (2012-2017)
Table United States Biologic Drugs Revenue Share by Region (2012-2017)
Figure United States Biologic Drugs Revenue Market Share by Region (2012-2017)
Figure United States Biologic Drugs Revenue Market Share by Region in 2016
Table United States Biologic Drugs Price (USD/Unit) by Region (2012-2017)
Table United States Biologic Drugs Sales (K Units) by Type (2012-2017)
Table United States Biologic Drugs Sales Share by Type (2012-2017)
Figure United States Biologic Drugs Sales Share by Type (2012-2017)
Figure United States Biologic Drugs Sales Market Share by Type in 2016
Table United States Biologic Drugs Revenue (Million USD) and Market Share by Type (2012-2017)
Table United States Biologic Drugs Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Biologic Drugs by Type (2012-2017)
Figure Revenue Market Share of Biologic Drugs by Type in 2016
Table United States Biologic Drugs Price (USD/Unit) by Types (2012-2017)
Figure United States Biologic Drugs Sales Growth Rate by Type (2012-2017)
Table United States Biologic Drugs Sales (K Units) by Application (2012-2017)
Table United States Biologic Drugs Sales Market Share by Application (2012-2017)
Figure United States Biologic Drugs Sales Market Share by Application (2012-2017)
Figure United States Biologic Drugs Sales Market Share by Application in 2016
Table United States Biologic Drugs Sales Growth Rate by Application (2012-2017)
Figure United States Biologic Drugs Sales Growth Rate by Application (2012-2017)
Table Roche Basic Information List
Table Roche Biologic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Roche Biologic Drugs Sales Growth Rate (2012-2017)
Figure Roche Biologic Drugs Sales Market Share in United States (2012-2017)
Figure Roche Biologic Drugs Revenue Market Share in United States (2012-2017)
Table Abbott Laboratories Basic Information List
Table Abbott Laboratories Biologic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Abbott Laboratories Biologic Drugs Sales Growth Rate (2012-2017)
Figure Abbott Laboratories Biologic Drugs Sales Market Share in United States (2012-2017)
Figure Abbott Laboratories Biologic Drugs Revenue Market Share in United States (2012-2017)
Table Johnson & Johnson Basic Information List
Table Johnson & Johnson Biologic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Johnson & Johnson Biologic Drugs Sales Growth Rate (2012-2017)
Figure Johnson & Johnson Biologic Drugs Sales Market Share in United States (2012-2017)
Figure Johnson & Johnson Biologic Drugs Revenue Market Share in United States (2012-2017)
Table Merck & Co. Basic Information List
Table Merck & Co. Biologic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Merck & Co. Biologic Drugs Sales Growth Rate (2012-2017)
Figure Merck & Co. Biologic Drugs Sales Market Share in United States (2012-2017)
Figure Merck & Co. Biologic Drugs Revenue Market Share in United States (2012-2017)
Table Pfizer Basic Information List
Table Pfizer Biologic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Pfizer Biologic Drugs Sales Growth Rate (2012-2017)
Figure Pfizer Biologic Drugs Sales Market Share in United States (2012-2017)
Figure Pfizer Biologic Drugs Revenue Market Share in United States (2012-2017)
Table Amgen Basic Information List
Table Amgen Biologic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Amgen Biologic Drugs Sales Growth Rate (2012-2017)
Figure Amgen Biologic Drugs Sales Market Share in United States (2012-2017)
Figure Amgen Biologic Drugs Revenue Market Share in United States (2012-2017)
Table Sanofi Basic Information List
Table Sanofi Biologic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Sanofi Biologic Drugs Sales Growth Rate (2012-2017)
Figure Sanofi Biologic Drugs Sales Market Share in United States (2012-2017)
Figure Sanofi Biologic Drugs Revenue Market Share in United States (2012-2017)
Table Novartis Basic Information List
Table Novartis Biologic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Novartis Biologic Drugs Sales Growth Rate (2012-2017)
Figure Novartis Biologic Drugs Sales Market Share in United States (2012-2017)
Figure Novartis Biologic Drugs Revenue Market Share in United States (2012-2017)
Table Eli Lilly Basic Information List
Table Eli Lilly Biologic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Eli Lilly Biologic Drugs Sales Growth Rate (2012-2017)
Figure Eli Lilly Biologic Drugs Sales Market Share in United States (2012-2017)
Figure Eli Lilly Biologic Drugs Revenue Market Share in United States (2012-2017)
Table Amgen Basic Information List
Table Amgen Biologic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Amgen Biologic Drugs Sales Growth Rate (2012-2017)
Figure Amgen Biologic Drugs Sales Market Share in United States (2012-2017)
Figure Amgen Biologic Drugs Revenue Market Share in United States (2012-2017)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Biologic Drugs
Figure Manufacturing Process Analysis of Biologic Drugs
Figure Biologic Drugs Industrial Chain Analysis
Table Raw Materials Sources of Biologic Drugs Major Players/Suppliers in 2016
Table Major Buyers of Biologic Drugs
Table Distributors/Traders List
Figure United States Biologic Drugs Sales Volume (K Units) and Growth Rate Forecast (2017-2022)
Figure United States Biologic Drugs Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure United States Biologic Drugs Price (USD/Unit) Trend Forecast (2017-2022)
Table United States Biologic Drugs Sales Volume (K Units) Forecast by Type (2017-2022)
Figure United States Biologic Drugs Sales Volume (K Units) Forecast by Type (2017-2022)
Figure United States Biologic Drugs Sales Volume (K Units) Forecast by Type in 2022
Table United States Biologic Drugs Sales Volume (K Units) Forecast by Application (2017-2022)
Figure United States Biologic Drugs Sales Volume (K Units) Forecast by Application (2017-2022)
Figure United States Biologic Drugs Sales Volume (K Units) Forecast by Application in 2022
Table United States Biologic Drugs Sales Volume (K Units) Forecast by Region (2017-2022)
Table United States Biologic Drugs Sales Volume Share Forecast by Region (2017-2022)
Figure United States Biologic Drugs Sales Volume Share Forecast by Region (2017-2022)
Figure United States Biologic Drugs Sales Volume Share Forecast by Region in 2022
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources